Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Says Bedaquiline TB Treatment Cost ‘Fair,’ $1/Day Price ‘Unrealistic’

Executive Summary

Johnson & Johnson maintains its game-changing antibiotic bedaquiline for drug-resistant tuberculosis is priced "fairly" at $400 for a six-month course, and terms calls by public health advocates to cut the cost to $1 a day “not realistic.”

You may also be interested in...



Big Pharma Advances Efforts In TB But Pricing Stays Key Concern

Price cuts, new treatments for TB and alliances to improve access to these medicines were among the key talking points at the recently concluded Union World Conference on Lung Health in India. TB survivors and activists were also vocal and pressed hard for their demands to be heard.

Janssen India MD To Depart

Significant leadership change is underway at J&J India, with Janssen India chief Sanjiv Navangul on his way out. He will be succeeded by senior J&J hand, Sarthak Ranade, who will need to handle some delicate issues pertaining to Sirturo while also keeping the flow of innovative products from the parent company to India going.

Hips Don’t Lie: J&J Faces Compensation Maelstrom In India Over Faulty ASR Implants

Johnson & Johnson is caught in the eye of a storm in India, after an expert panel recommended compensation for patients affected by its 'faulty' ASR hip implants.  A stinging report by the panel raises several questions around J&J’s alleged “lack of seriousness” in addressing the issue - charges that the company denies - though it remains to be seen how the Indian government ensures that Indian patients get a fair deal.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124843

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel